{"entity":{"id":"nct07126158","kind":"trial","name":"Stereotactic Body Radiotherapy Plus FAK and RAF/MEK Inhibition in Advanced Pancreatic Adenocarcinoma","aka":[],"tldr":"A phase 2 trial of avutometinib + defactinib in pancreatic cancer, run by Washington University School of Medicine, now recruiting.","summary":"Stereotactic Body Radiotherapy Plus FAK and RAF/MEK Inhibition in Advanced Pancreatic Adenocarcinoma is a phase 2, randomised interventional study registered as NCT07126158 by Washington University School of Medicine, with a registry enrolment figure of 36 participants, started 2026-04-10 and due to reach its primary completion in 2030-04-30. Interventions recorded: Stereotactic body radiotherapy; Defactinib; Avutometinib. Conditions listed: Pancreatic Adenocarcinoma; Cancer of the Pancreas; Pancreas Cancer; Pancreatic Cancer. Primary outcome: Progression-free survival (PFS) - Experimental Arm Only. Pancreatic eligibility wording from the registry: \"* Histologically or cytologically confirmed advanced pancreatic adenocarcinoma that is considered borderline resectable or locally advanced per institutional standardized criteria of unresectability or medical inoperability (NCCN guidelines 2\". Sites: United States. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT07126158","url":"https://clinicaltrials.gov/study/NCT07126158"}],"tags":["ctgov-ingest","pancreatic-deep-dive"],"related":[],"cancers":["borderline-resectable-pdac","resectable-pdac","locally-advanced-pdac"],"sections":[],"technologies":["sbrt"],"targets":[],"drugs":["avutometinib-defactinib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07126158","phase":"2","setting":"Phase II Study of Stereotactic Body Radiotherapy Plus FAK and RAF/MEK Inhibition in Advanced Pancreatic Adenocarcinoma","sponsor":"Washington University School of Medicine","enrolled":36,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07126158/","neighbours":{"cancer":[{"id":"borderline-resectable-pdac","kind":"cancer","name":"Borderline resectable pancreatic ductal adenocarcinoma","route":"/cancers/borderline-resectable-pdac/"},{"id":"locally-advanced-pdac","kind":"cancer","name":"Locally advanced unresectable pancreatic ductal adenocarcinoma","route":"/cancers/locally-advanced-pdac/"},{"id":"resectable-pdac","kind":"cancer","name":"Resectable pancreatic ductal adenocarcinoma","route":"/cancers/resectable-pdac/"}],"technology":[{"id":"sbrt","kind":"technology","name":"SBRT / SABR (stereotactic radiotherapy)","route":"/technologies/sbrt/"}],"drug":[{"id":"avutometinib-defactinib","kind":"drug","name":"Avutometinib + defactinib","route":"/drugs/avutometinib-defactinib/"}],"term":[{"id":"pancreatic-trials-open-today","kind":"term","name":"Pancreatic cancer trials open today (registry snapshot and UK sites)","route":"/terms/pancreatic-trials-open-today/"}]}}